2 results
Approved WMOPending
The primary objective is to characterize the change in the Pharmacodynamic (PD) biomarker, fecal calprotectin, during treatment with anrukinzumab.The secondary objectives include:* Characterization of the PK profile and total IL-13 of three multiple…
Approved WMOCompleted
The main objective of the study is to test if burst SCS is clinically non-inferior to conventional SCS in patients already successfully treated with conventional SCS. The secondary objective of the study is to evaluate patient satisfaction and…